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Abstract The cytokine interleukin-6 (1L-6), a key mediator of 
immune and acute phase responses of the liver, has also been 
implicated in uterine functions. Estrogens are potent repressors 
of IL-6 production by uterine stromal cells. In the endometrial 
adenocarcinoma cell line Ishikawa, phorbol ester-induced 
activation of the IL-6 promoter was inhibited to basal levels by 
17ß-estradiol (E2) in a wild-type receptor-dependent fashion. 
Although tamoxifen has been shown to have estrogenic effects on 
the endometrium, it did not inhibit induction of the IL-6 
promoter. We previously showed that inhibition of IL-6 gene 
expression by E2 does not involve high-affinity binding of the 
estrogen receptor (ER) to IL-6 DNA. We now report that the ER 
can directly interact with the transcription factors NF-IL6 and 
NF-KB and can inhibit their ability to bind DNA which might be 
the molecular basis for repression of IL-6 gene expression by 
estrogens. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Interleukin-6 (IL-6) is a pleiotropic cytokine produced in 
response to infection, injury or trauma by a wide variety of 
cells including monocytes/macrophages, fibroblasts, epithelial 
cells and endothelial cells [1]. In turn, IL-6 acts on a wide 
variety of cells regulating immune responses, acute phase re-
sponses of the liver, hematopoiesis, neuronal functions and 
osteoclastogenesis [1,2]. Although IL-6-deficient mice do not 
display any obvious defects in development, absence of IL-6 
perturbs immune and acute phase responses in these mice 
[3,4]. Strikingly, ovariectomy in the IL-6-deficient mice ab-
lated the osteoporosis that was seen in normal mice suggesting 
an important role for IL-6 in mediating bone loss in an estro-
gen-depleted state [4]. IL-6 has also been implicated in uterine 
functions [1,3-6]. Both uterine stromal fibroblasts and epithe-
lial cells produce IL-6 which can be inhibited by 17ß-estradiol 
(E2) [5,6]. This is of considerable interest since particular cy-
tokines are now known to have either positive or negative 
effects on blastocyst implantation and embryo development. 
For example, it has been suggested that IL-6 via its induction 
of chondroitin sulfate proteoglycans inhibits balstocyst im-
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plantation [6]. Deficiency of a related cytokine leukemia in-
hibitory factor (LIF) in female mice leads to failure of blas-
tocyst implantation and development [7]. Inhibition of IL-6 
production by estrogens suggests that the hormonal control of 
these processes may be, at least partly, regulated via modu-
lations of local cytokine production. 
Our earlier studies showed that 225 bp of the IL-6 5'-flank-
ing region is sufficient for conferring responsiveness of the IL-
6 promoter to cytokines such as IL-1 and activators of protein 
kinase C (phorbol esters) and protein kinase A (forskolin) [8-
11]. We and others showed that the activation of the IL-6 
promoter involves synergism between the transcription factors 
NF-IL6 (also called CAAT enhancer binding protein/ß or C/ 
EBPß) and N F - K B [11,12]. We also showed that while multi-
ple agents activate IL-6 gene transcription, glucocorticoids 
and estrogens are potent repressors of IL-6 gene expression 
[5,9-11,13]. It appears that negative feedback by steroid hor-
mones on endogenous IL-6 levels is an important regulator of 
physiological homeostasis. Disruption of this control, as in an 
estrogen-depleted state in post-menopausal women, is believed 
to be the major reason for uninhibited IL-6 production in the 
post-menopausal phase that ultimately precipitates osteoporo-
sis [14,15]. Indeed, E2 down-modulates IL-6 production in 
osteoblasts and in bone marrow stromal cells [14-17]. Under-
standing the molecular mechanisms that control steroid regu-
lation of key cytokine genes, therefore, represents an impor-
tant facet of endocrinology/immunobiology. 
The DNA elements in the IL-6 5' flanking sequence that 
respond to inhibition by steroid hormones in functional assays 
do not bind either the glucocorticoid receptor (GR) or the 
estrogen receptor (ER) [10,11,13,18]. Our investigations of 
the mechanisms by which glucocorticoids inhibit IL-6 gene 
transcription revealed direct physical association and func-
tional antagonism between the GR and N F - K B [11]. Negative 
cross-talk between the GR and N F - K B was also reported by 
Caldenhoven et al. and Scheinman et al. [19,20]. 
In these studies, we investigated the effects of E2 and ta-
moxifen on phorbol ester-induced activation of the IL-6 pro-
moter in the endometrial adenocarcinoma cell line Ishikawa 
that was created by Nishida et al. as a model for studies of 
effects of E2 on endometrial tumors [21]. Our studies suggest 
that estrogens repress IL-6 gene expression through inhibition 
of the DNA-binding activities of the transcription factors NF-
IL6 and N F - K B by the ER. 
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2. Materials and methods 
2.1. Cell culture and transfections 
Ishikawa cells were provided by Drs. Erlio Gurpide and Stephanie 
DeGrandis. The cells were cultured in minimal essential medium 
(MEM) with Earle's salt and 10% fetal bovine serum (FBS). While 
stock cells were grown in MEM containing regular FBS, cells used in 
experiments were maintained for at least 8 days in phenol red-free 
MEM supplemented with dextran-coated charcoal-treated serum with 
change of medium every 3 days. Cells were transfected by the calcium 
phosphate coprecipitation procedure as previously described [8-11]. 
Cells were transfected with pIL225 (2 ug) in the presence or absence 
of an expression vector for wild-type or mutant ER (2 ug) together 
with the carrier DNA pGEM7Zf(+) to make up the total DNA to 10 
ug per 60 mm petri dish. Luciferase assays were performed using a kit 
(Promega) following instructions of the manufacturer and measured 
in a Lumat LB9501 luminometer (Berthold, Germany). In each ex-
periment, equal amounts of protein, as measured by the Bradford 
method (BioRad), were assayed for luciferase activity. Each experi-
ment was repeated at least 3 times. 
2.2. Plasmid constructs 
The construct pIL225 containing IL-6 gene sequences from —225 to 
+ 13 linked to the luciferase gene has been described previously [22]. 
The expression vectors for wild-type and mutant ERs were gifts of Dr. 
Pierre Chambon. 
2.3. Preparation of His-tagged ER 
The ER cDNA was derived from the expression vector HEO and was 
cloned in frame into the plasmid pET15b (Novagen) for protein ex-
pression. The recombinant plasmid was transformed into host bacteria 
(BL21) harboring a T7 polymerase gene in a X lysogen (XDE3) under 
the control of a lacUV5 promoter. His-ER was purified by affinity 
chromatography on Ni2+-nitriloacetic acid agarose beads. The beads 
were extensively washed and bound protein was eluted in a buffer 
containing 80 mM imidazole. His-ß-gal was expressed from a 
pET15b-ß-gal plasmid construct. The purification protocol was identi-
cal to that described above except the elution buffer contained 200 mM 
imidazole. The purified proteins were applied to Centricon 10 columns 
(Amicon) to remove imidazole and further concentrate the proteins. 
2.4. Co-immunoprecipitation experiments 
The cDNAs for ER, p65, bzipNF-IL6 (containing amino acids 141-
296 of murine NF-IL6) and I K B R were translated in vitro using 
wheat-germ extracts following instructions of the manufacturer 
(Promega) with one modification. At the end of the incubation period, 
the reactions were terminated by the addition of RNase A to a final 
concentration of 200 ug/ml followed by a brief incubation at 30°C. 
Individual extracts were appropriately mixed and incubated in a buff-
er containing 20 mM Hepes, pH 7.9, 50 mM KC1, 2.5 mM MgCl2, 
1 mM DTT, 1 mM PMSF and 10% glycerol for 45 min at room 
temperature. To rule out the possibility of co-immunoprecipitation 
of proteins due to adventitious binding to template DNA provided 
in the in vitro transcription/translation reactions, ethidium bromide at 
a concentration of 12.5 ug/ml was included in the reactions. DNA-
dependent protein associations are selectively inhibited by ethidium 
bromide in immunoprecipitation reactions without adversely affecting 
DNA-independent protein associations [23]. The mixtures were di-
luted to 200 ill with NET buffer containing 50 mM Tris-HCl, pH 
7.5. 150 mM NaCl, 1 mM EDTA, 0.1% NP-40, 0.25% gelatin and 
1 mM PMSF. The protein mixture was precleared by the addition of 
30 ul of protein-A Sepharose beads for 1 h at 4°C. The beads were 
spun down, appropriate antisera were added to the supernatants and 
the beads were left on a rotary shaker overnight at 4°C. The beads 
were washed 2 times with NET buffer and once with a buffer con-
taining 10 mM Tris-HCl, pH 7.5 and 0.1% NP-40 (1 ml each time). 
The immune complexes were boiled in 2X SDS sample buffer con-
taining 10% ß-mercaptoethanol and analysed by SDS-PAGE, fluorog-
raphy and autoradiography. The anti-p65 antiserum was an affinity-
purified rabbit polyclonal antibody raised against a peptide mapping 
with the amino terminal re/-related region of the p65 subunit of hu-
man N F - K B (Santa Cruz Biotechnology). The anti-NF-IL6 and the 
anti-lKBR antisera were rabbit polyclonal antisera raised by us 
against the glutathione S-transferase (GST) fusion proteins GST-
NF-IL6 and G S T - I K B R [24] respectively. 
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2.5. Electrophoretic mobility shift assays (EMSA) 
EMSAs were done using His-tagged ER, in vitro-translated (using 
wheat-germ extract, Promega) p65 or NF-IL6 or recombinant p50 
(Promega). Conditions for EMSAs were essentially as described pre-
viously [24] with slight modifications. Briefly, for NF-IL6, 1 ul of in 
vitro-translated protein was pre-incubated in the presence or absence 
of antibodies or competitor proteins for 30 min on ice in a buffer 
containing 10 mM Hepes, pH 7.9, 50 mM NaCl, 1 mM DTT, 1 mM 
MgCl2, 0.1 mM EDTA and 10% glycerol, 5 ug/ml poly dl-poly dC, 
200 ug/ml of BSA and a protease inhibitor cocktail (Boehringer 
Mannheim) before addition of the labeled probe and further incuba-
tion at room temperature for 15 min. In the case of p50 and p65, the 
conditions were the same except no EDTA or MgCl2 was added. 
Probes used were a 32P-labeled double-stranded oligonucleotide con-
taining the N F - K B sequence derived from the IL-6 promoter (nucleo-
tides —64 to —73) or a commercial (Santa Cruz Biotechnology, Inc.) 
oligonucleotide containing the consensus core NF-IL6 binding 
sequence (TTGCGCAA) which is only different by one base from 
the NF-IL6 site (TTGTGCAA) present between nucleotides -148 
and —155 in the IL-6 promoter [11]. All antisera were purchased 
from Santa Cruz Biotechnology, Inc., except the anti-Fos antibody 
which was purchased from Oncogene Science. The binding reactions 
were analyzed by electrophoresis on 6% native polyacrylamide gels 
(acrylamide/bisacrylamide=30:l). Electrophoresis was carried out at 
200 V in 0.5XTBE (1 X =0.05 M Tris base, 0.05 M boric acid and 1.0 
mM EDTA) at 4°C. Gels were dried and subjected to autoradiogra-
phy. 
3. Results 
3.1. Inhibition of phorbol ester-induced activation of the IL-6 
promoter by ERIE2 combination: absence of inhibition by 
Tarn 
The IL-6 promoter containing 225 bp of 5' flanking sequen-
ces is activated by diacylglycerol/activators of protein kinase 
C in many different cell types including fibroblasts, epithelial 
cells and osteoblasts [8,18,25]. In Ishikawa cells, we observed 
a 6-10-fold activation of the IL-6 promoter upon stimulation 
with the phorbol ester phorbol 12-myristate 13-acetate (PMA) 
(Fig. 1). Ishikawa cells were previously reported to be E R 
positive [26]. However, after maintenance in culture for pro-
longed periods of time, particularly under certain culture con-
ditions, they become unresponsive to E2 (ref. [27] and E. 
Gurpide, personal communication). The lack of responsive-
ness of these cells to E2 could be due to down-regulation of 
ER expression in more differentiated cells [28]. Indeed, in cells 
transfected with pIL225 alone, PMA-induced expression from 
the IL-6 promoter was repressed only between 20 and 40% in 
the presence of E2 but upon cotransfection with HEO, an 
expression vector containing the wild-type human ER [29], 
the induction was inhibited to almost basal levels (Fig. 1). 
HEO has been extensively used previously in studies of estro-
gen-induced promoters [30,31]. Earlier, we and others demon-
strated the ability of HEO to also efficiently repress IL-6 pro-
moter activity [13,18]. In these studies we also investigated the 
ability of the anti-estrogen tamoxifen (Tarn) to repress IL-6 
promoter activity in the presence of HEO (Fig. 1) or mutan t 
receptors (Fig. 2) essentially for two reasons: (i) the effect of 
Tarn on inhibition of gene expression has not been adequately 
investigated in any estrogen-responsive cell including Ishikawa 
cells and (ii) T a m has been shown to have partial agonist 
activity in the endometr ium; several recent studies have sug-
gested a possible link between tamoxifen use and the develop-
ment of endometrial carcinoma [32,33]. In our studies, used at 
either 1 0 - 7 M or even higher concentrations, T a m did not 
display any inhibitory effect on IL-6 promoter activity thus 
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Fig. 1. Effect of E2 and Tarn on PMA-induced IL-6 promoter activ-
ity in Ishikawa cells. Monolayer cultures of Ishikawa cells were 
transfected with the IL-6/luciferase construct pIL225 (2 u.g) and a 
carrier DNA pGEM7Zf(+) (to make up to 10 ug/60 mm petri dish) 
in the presence or absence of an expression vector for wild-type 
(HEO) (2 ug). Cells were transfected by the calcium phosphate co-
precipitation procedure [45] as previously described [8-11]. At 16-
18 h post-transfection, the precipitate was washed off and the plates 
were replenished with serum-free medium in the presence or absence 
of PMA (100 ng/ml), E2 or Tam (both at 10-7 M). Identical data 
were obtained with 10-fold lower concentrations of E2 or Tam. The 
cells were harvested 6 h later and cell extracts prepared by freezing 
and thawing of the cells were assayed for protein amounts. Extracts 
containing equal amounts of protein were assayed for luciferase ac-
tivity. The fold-inductions represent luciferase activities in induced 
cultures relative to those in uninduced control cultures. Values are 
mean ± SE of three independent experiments. 
demonstrating the strict estrogen-dependence of ER for re-
pression of IL-6 promoter activity (Fig. 1). 
3.2. Structural requirements in ER for repression of IL-6 
promoter activity 
The ER, like other hormone receptors, has a modular struc-
ture with distinct functions for each domain, as was previ-
ously determined using estrogen-stimulated promoters 
[30,31]. For example, domain C is the DNA-binding domain, 
domains B and E encompass two non-acidic independent 
transcriptional activation domains called TAF-1 and TAF-2 
respectively and domain E is the hormone-binding domain 
(Fig. 2A). Also, the ER was shown to bind to estrogen re-
sponse elements as a ligand-induced dimer [31]. We used ex-
pression vectors for different mutant ERs (all derived from 
HEO) in transfection experiments to evaluate the role of 
some of the domains in repression of phorbol ester-induced 
IL-6 promoter activity (Fig. 2B). A deletion extending from 
the hinge region D into the hormone-binding domain E 
(HE5), previously shown to abolish estrogen binding was un-
able to repress IL-6 promoter activation. This was similar to 
our previous observations in HeLa cells [13]. However, a de-
letion of the hinge region alone (HE 12) did not impair the 
ability of ER to inhibit IL-6 promoter activation. The mutant 
HE 11 containing a deletion in the DNA-binding domain was 
unable to behave as a repressor (Fig. 2). Curiously, this mu-
tant slightly augmented the phorbol ester induced stimulation 
of IL-6 promoter function (Fig. 2B). The mutant HE 14 con-
taining an intact hormone-binding domain but devoid of 
TAF-1 and the DNA-binding domain (deletion of amino 
acids 1-281) was not able to repress the IL-6 promoter. 
HE 15 containing TAF-1 and the DNA-binding domain, but 
lacking TAF-2 and the hormone-binding domain also did not 
repress the IL-6 promoter. Conversely, HE 19, lacking the 
TAF-1 domain but with intact DNA-binding domain and 
hormone-binding domain containing the hormone-inducible 
transactivating function-2 (TAF-2), repressed activation of 
the IL-6 promoter by up to 80-90%. Taken together, these 
data establish a clear dependence of the ER on the DNA-
binding domain (mutants HE11, HE 14) and the hormone 
binding domain (HE5, HE15) for repression of the IL-6 pro-
moter in Ishikawa cells. 
3.3. Direct interactions between ER and transcription factors 
NF-IL6 and NF-KB 
We and others previously established the importance of the 
N F - K B site and the NF-IL6 site in the IL-6 promoter for its 
activation by multiple agents including cytokines, viruses and 
activators of protein kinase C (diacylglycerols/phorbol esters) 
and protein kinase A (forskolin, cAMP analogues) 
[9,11,25,34-37]. Furthermore, the p65 subunit of N F - K B 
(and also the p50 subunit, albeit less efficiently) and NF-IL6 
were found to synergize in the activation of the IL-6 promoter 
[11,12]. The PMA-induced activation of the IL-6 promoter in 
Ishikawa cells was also found to be dependent on intact NF-
KB and NF-IL6 sites in the promoter (data not shown). In our 
initial investigations of repression of IL-6 promoter activation 
by E2, we were unable to detect binding of the ER to the 
promoter region between -225 and +13 that could be func-
tionally repressed in transfection experiments [13]. This sug-
gested that inhibition of NF-IL6- and p65-mediated activation 
of this region of the promoter by E2 may be a consequence of 
physical interaction between the ER and the transcription 
factors involved in activation of the IL-6 promoter [13,18]. 
To examine this possibility, we investigated direct interactions 
of the ER with both p65 and NF-IL6 by co-immunoprecipi-
tation methods. Full length p65 and the ER and a region of 
NF-IL6 comprising amino acids 141-296 of NF-IL6 contain-
ing the basic amino acid-leucine zipper (bzip) domain of the 
protein (amino acids 206-296) (bzipNF-IL6) were synthesized 
in vitro using wheat-germ extracts. To distinguish between the 
ER and p65, which are of identical molecular size (65 kDa), 
the ER was synthesized in the presence of [35S]methionine 
while p65 was synthesized in the presence of unlabeled amino 
acids. For the sake of uniformity, bzipNF-IL6 was also syn-
thesized in the presence of unlabeled amino acids. Interactions 
of the ER with NF-IL6 or N F - K B were found to be estrogen-
independent just as the GR can interact with these transcrip-
tion factors in the absence of its ligand [11,19,20,38]. As a 
negative control, we used an unrelated protein IKBR, a mem-
ber of the iKB-family of proteins, whose cDNA was recently 
cloned by us [24]. I K B R was also synthesized in the presence 
of unlabeled amino acids. The translation mixtures were 
briefly treated with RNase following the recommended incu-
bation period, to ensure that no labeled p65 or NF-IL6 or 
I K B R would be made once it was mixed with extract contain-
ing labeled ER and unreacted [35S]methionine. Also, ethidium 
bromide was included in the incubation mixtures to inhibit 
adventitious DNA-mediated protein interactions. The pres-
ence of unlabeled p65 or NF-IL6 proteins in the respective 
programmed wheat-germ extract was verified by assaying the 
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Fig. 2. Structural requirements in the ER for repression of IL-6 promoter activity in the presence of E2. Cells were transfected with pIL225, in 
the presence or absence of HEO or expression vectors for mutant ERs. All other conditions were as described in the legend to Fig. 1. Data 
shown are mean ± SE of three independent experiments. 
ability of the proteins to bind to target sites in DNA in EM-
SAs and the presence of I K B R in the extract was verified by 
Western blotting (data not shown). 
35S-labeled ER was incubated in buffer in the presence or 
absence of unlabeled p65 or NF-IL6 or IKBR. Subsequently, 
these reactions were immunoprecipitated either with an anti-
p65 antibody, an anti-NF-IL6 antibody, an anti-lKBR anti-
body or with control immunoglobulin. The immunoprecipi-
tated material was analyzed by SDS-polyacrylamide gel elec-
trophoresis and fluorography. The anti-p65 antibody did not 
precipitate labeled ER in the absence of p65 (Fig. 3, lane 2). 
Likewise, anti-NF-IL6-antibody did not precipitate labeled 
ER in the absence of NF-IL6 (lane 5). However, in the pres-
ence of the respective proteins, both the antibodies precipi-
tated ER (lanes 3 and 6) indicating interactions of the ER 
with both p65 and NF-IL6. In parallel reactions, control im-
munoglobulin did not precipitate ER (lanes 2 and 4). No 
immunoprecipitation of ER was detected by either control 
serum or specific antiserum in the reactions containing I K B R 
(lanes 7-9). 
3.4. ER inhibits the DNA-binding ability ofNF-IL6 and NF-KB 
subunits 
We investigated whether direct association between the ER 
and the transcription factors NF-IL6 and N F - K B affects the 
binding of these proteins to their target sites in the IL-6 pro-
moter in EMSAs. The NF-IL6 protein and the p65 subunit of 
N F - K B were obtained by in vitro translations of the respective 
full-length cDNAs. The ER that we used in these assays was a 
recombinant His-tagged receptor. To discount any effects of 
the His tag in ER, we used His-tagged ß-gal as a control. As 
illustrated in Fig. 4A (lanes 4-6), the DNA-binding activity of 
NF-IL6 was significantly inhibited by His-ER. His-ß-gal had 
no effect on the binding of NF-IL6 indicating that the effects 
of His-ER were mediated by the ER part of the fusion pro-
tein. 
We next investigated the effect of the ER on the DNA-
binding ability of the p65 subunit of N F - K B . The molecules 
smaller than p65 appear to be truncated forms of in vitro 
translated p65. The ER minimally affected the DNA-binding 
ability of p65 (Fig. 4B, lanes 4-6). Our inability to detect a 
significant inhibition in the DNA binding ability of p65 in the 
presence of the ER, despite evidence for interaction between 
the two proteins by co-immunoprecipitation techniques, may 
be due to lack of optimal conditions for detection by EMSA. 
Similarly, in the case of the GR, while an interaction between 
the GR and NF-IL6 was demonstrated by co-immunoprecip-
itation techniques, evidence for such an interaction could not 
be demonstrated by EMSA [38]. However, in the same experi-
ment and under similar conditions, the ER strongly inhibited 
the ability of the p50 homodimer to bind DNA (Fig. 4C, lanes 
4—6). The control protein His-ß-gal did not influence the bind-
ing of p65 (Fig. 4B, lanes 7-9) but surprisingly increased the 
binding activity of p50 and by itself formed a slower migrat-
ing complex with the N F - K B probe (Fig. 4C, lanes 7-9). We 
and others have shown that NF-IL6 can efficiently synergize 
with N F - K B to activate the IL-6 promoter [11,12]. Therefore, 
an inhibition of the DNA-binding activity of p50 by the ER, 
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Fig. 3. Co-immunoprecipitation of ER-NF-IL6 and ER-p65 complexes. 35S-labeled ER and unlabeled p65, bzipNF-IL6 or IKBR were trans-
lated in wheat germ extracts. 10 ul aliquots of the programmed extract containing labeled ER (treated with RNase to prevent any further syn-
thesis of proteins when mixed with extracts containing unlabeled proteins) were incubated in the presence or absence of p65 (10 ul), NF-IL6 
(10 i^l), IKBR (10 ul), anti-p65 antibody, anti-NF-IL6 antiserum, anti-lKBR antiserum or control immunoglobulm. The relative amounts of the 
translated proteins p65, bzipNF-IL6 and IKBR present in the wheat germ extracts were predetermined by analysing 35S-labeled proteins on 
SDS-gels and normalizing the radioactivity incorporated in the proteins relative to the content of methionine in each protein. Equal volumes of 
the extracts were found to contain approximately similar amounts of the respective proteins. The proteins were immunoprecipitated as de-
scribed under Section 2 and the resulting complexes were analyzed by fluorography following separation on an 10% SDS-polyacrylamide gel. 
The mobilities of the protein standards are indicated. 
which in all likelihood is also through direct association be-
tween the two proteins, will considerably diminish occupancy 
of the N F - K B site in the IL-6 promoter by the active N F - K B 
complex. Also, since the NF-IL6 and N F - K B sites are both 
crucial for IL-6 promoter function [11,12], inhibition of the 
DNA-binding activity of NF-IL6 alone would disrupt activa-
tion of the promoter. 
4. Discussion 
Repression of cytokine gene expression, such as that of IL-
6, by endogenous estrogens and corticosteroids represents an 
important immunoregulatory feature of steroid hormones. 
Steroid receptors mediate the specific response of cells to their 
respective ligands, in many instances, by virtue of their ability 
to bind as-acting enhancer sequences termed steroid response 
elements. Although activation of genes by glucocorticoids and 
estrogens typically is mediated by binding of the ligand-acti-
vated receptor to the respective response element(s) present 
upstream of or within target genes, negative regulation by 
these hormones cannot be adequately explained by receptor-
DNA interactions. Therefore, the molecular targets that de-
termine inhibition of gene expression by steroid hormones is a 
subject of intense investigation in many laboratories. Our 
studies are the first to show the ability of the ER to compro-
mise the DNA-binding activities of NF-IL6 and N F - K B . 
Although transcriptional interference between ER and Fos/ 
Jun (AP-1) was described previously using synthetic AP-1 
oligonucleotide-driven reporter genes [39], functional antago-
nism between the ER and NF-IL6/NF-KB demonstrate nega-
tive cross-talk in the context of a biologically important mol-
ecule which regulates normal physiological responses such as 
endometrial functions [5,6] and bone metabolism [2,14]. 
Although the anti-estrogen Tarn has been shown to have 
estrogen-like activities in the endometrium, it was ineffective 
in repressing IL-6 promoter function in the presence of wild-
type ER. This suggests that adjuvant Tarn therapy for ER-
positive breast cancers in post-menopausal women may not 
alleviate the elevated systemic IL-6 level that has been sug-
gested to contribute to osteoporosis in these women [2]. 
In our previous studies on the mechanisms by which glu-
cocorticoids inhibit IL-6 gene expression, we found no evi-
dence for interactions between the GR and IL-6 DNA using 
a variety of techniques [9,10]. We subsequently demonstrated 
functional antagonism between the p65 subunit of N F - K B and 
the GR [11]. Specifically, we showed mutual interference in 
transactivation functions between the GR and the p65 subunit 
of N F - K B in functional assays and direct physical association 
between the two proteins in co-immunoprecipitation experi-
ments [11]. In other studies, interactions between the GR and 
NF-IL6 were also demonstrated [38]. 
In our initial investigations of the mechanisms of repression 
of IL-6 promoter activity by estrogens, we and others showed 
that like the GR, the ER also does not bind with high affinity 
to IL-6 DNA [13,18]. However, mutations in the DNA-bind-
ing domain of the ER was unable to repress IL-6 promoter 
activity in HeLa cells [13]. In Ishikawa cells too, deletion of 
the DNA-binding domain (with intact TAF-1 and TAF-2 
84 P. Ray et al.lFEBS Letters 409 (1997) 79-85 
Fig. 4. Effect of the ER on the DNA-binding abilities of different 
transcription factors. A: In vitro translated (1 u\l of translation mix) 
NF-IL6 was incubated in the presence or absence of anti-NF-IL6 
antibody or anti-GATA3 antibody (used as a negative control) or 5, 
50 or 250 ng of His-ER or equimolar amounts of His-ßgal protein. 
The samples were incubated with labeled probe before electrophore-
sis. The probe was a 32P-labeled commercial (Santa Cruz Biotech-
nology, Inc.) double-stranded oligonucleotide containing the consen-
sus core NF-IL6 binding sequence (TTGCGCAA) which is only 
different by one base from the one (TTGTGCAA) present between 
nucleotides —148 and —155 in the IL-6 promoter [11]. B,C: Effect 
of the ER on the DNA-binding abilities of the individual subunits 
of NF-KB. The DNA-binding reaction was carried out with (B) in 
vitro-translated p65 or (C) purified p50 protein (Promega) in the 
presence or absence of antibodies to the proteins as indicated, or in 
the presence of His-ER or equimolar amounts of His-ßgal. The 
probe used was a 32P-labeled oligonucleotide containing the NF-KB 
sequence from the IL-6 promoter. The binding reactions were ana-
lyzed by electrophoresis on 6% native polyacrylamide gels. Gels 
were dried and subjected to autoradiography. 
functions) totally abrogated repressor function of the recep-
tor. It is curious that this mutant receptor actually potentiated 
the activation of the promoter by PMA. This is reminiscent of 
our previous findings with first Zinc (Zn) finger mutants of the 
GR in which mutations in the first Zn-finger (but not the 
second Zn finger) of the GR caused a repressor to activator 
switch in the behavior of the receptor toward IL-6 promoter 
activity, which was even more obvious with suboptimal con-
centrations of IL-1 [10]. Furthermore, we found that specific 
promoters, otherwise unaffected by glucocorticoids and the 
wild-type GR were also activated by these mutant receptors 
suggesting that mutations in the DNA-binding domain of GR 
may unleash aberrant expression of genes which are not nor-
mally regulated by glucocorticoids [10]. Whether similar mu-
tations in the ER can also aberrantly activate specific genes 
remains to be determined. 
Small deletions in the ligand binding domain which are 
known to impair binding of estrogen to the ER, as in HE5, 
eliminated the ability of the receptor to inhibit IL-6 promoter 
activity. However, the hormone-binding domain alone con-
taining an intact TAF-2 function (which is ligand-inducible) 
was unable to cause repression. What appears clearly dispen-
sable for repression is the region (D) adjacent to the DNA-
binding domain of the ER. This is not particularly surprising 
since deletion or insertion mutations in this domain were pre-
viously shown to have little effect on the stimulatory effects of 
the receptor on some promoters. This region, which is con-
served neither in length nor in amino acid composition in 
different nuclear hormone receptors, and also poorly con-
served across species in the ER has been postulated to act 
as a hinge between the DNA- and hormone-binding domains 
[30,40]. The TAF-1 domain alone (in HE 15) was demon-
strated to have constitutive transactivational functions in a 
promoter- and cell-specific fashion [41]. Furthermore, this ac-
tivity strongly correlated with the agonistic activity of OH-
Tam in combination with the intact ER on the same genes in 
the same cells [41]. In our experiments the Tam/ER combina-
tion did not repress IL-6 promoter function which correlated 
with the inability of HE15 to repress. 
The data in Figs. 3 and 4 indicate that E2 is not required 
for interactions of the ER with NF-IL6 or N F - K B . These 
results are in agreement with previous reports demonstrating 
the ability of in vitro-synthesized ER to interact in vitro, in 
the absence of hormone, with a variety of proteins such as c-
Jun [42], the TBP associated factor (TAF) TAFu30 [43] and 
the co-activator SPT6 [44]. This is not a unique ability of the 
estrogen receptor since the structurally related glucocorticoid 
receptor synthesized in vitro also interacts with multiple tran-
scription factors in vitro in an hormone-independent fashion 
as has been shown by us [11] and other investigators 
[19,20,38]. It has been suggested that in vitro-synthesized ster-
oid receptors fold into conformations that are permissive for 
protein-protein interactions in vitro and therefore these inter-
actions are not influenced by hormone [20]. It is important to 
note, however, that although protein-protein interactions with 
in vitro-synthesized receptors are hormone-independent, these 
interactions occur only with specific proteins. 
Thus we have defined novel molecular targets for inhibition 
by estrogen that now provide a basis for the initial description 
of inhibition of IL-6 gene expression by E2 in freshly ex-
planted human endometrial stromal cells, osteoblasts and ute-
rine epithelial cells [5,6]. It can be speculated that other cyto-
kine genes that are regulated by a combination of NF-IL6 and 
N F - K B , such as IL-8, may also be subject to negative regu-
lation by estrogens by similar mechanisms. Protein-protein 
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interactions between hormone receptors and transcriptional 
activators resulting in inhibition of the DNA-binding func-
tions of the transactivators are likely integral to the complex 
interplay between hormones and the immune system. 
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